A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis-Reference-Cited by-同舟云学术

A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis

Published:2011 Issue:2 Volume:13 Page:R68
ISSN:1478-6354
Container-title:Arthritis Research & Therapy
language:en
Short-container-title:Arthritis Res Ther

Author:

Stump Kristine L,Lu Lily D,Dobrzanski Pawel,Serdikoff Cynthia,Gingrich Diane E,Dugan Ben J,Angeles Thelma S,Albom Mark S,Ator Mark A,Dorsey Bruce D,Ruggeri Bruce A,Seavey Matthew M

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference39 articles.

1. Nonresolving Inflammation

2. Inflammation: Gearing the journey to cancer

3. Therapeutic antibodies for autoimmunity and inflammation

4. Kinase inhibitors attract attention as oral rheumatoid arthritis drugs

5. Kinase inhibitors: a new approach to rheumatoid arthritis treatment

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High-throughput screening identification of novel immunomodulatory combinations for the generation of tolerogenic dendritic cells;Frontiers in Medicine;2024-01-05

2. Nucleolar Protein 56 Deficiency in Zebrafish Leads to Developmental Abnormalities and Anemia via p53 and JAK2-STAT3 Signaling;Biology;2023-03-31

3. Signaling pathways in rheumatoid arthritis: implications for targeted therapy;Signal Transduction and Targeted Therapy;2023-02-17

4. Canonical and noncanonical regulatory roles for JAK2 in the pathogenesis of rheumatoid arthritis‐associated interstitial lung disease and idiopathic pulmonary fibrosis;The FASEB Journal;2022-05-06

5. Rheumatoid Arthritis and JAK-STAT Inhibitors: Prospects of Topical Delivery;Current Drug Therapy;2022-04